Opendata, web and dolomites

MSCFate

Fate of mammary stem cells during tumorigenesis and clinical implications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MSCFate project word cloud

Explore the words cloud of the MSCFate project. It provides you a very rough idea of what is the project "MSCFate" about.

perturbation    msc    h1047r    consequently    investigation    elucidate    subunit    hypothesis    catalytic    reduces    kinase    breast    fate    unbiased    drug    standard    pik3ca    phosphoinositide    perturb    cell    situ    metastasis    vivo    regulates    cells    therapy    mammary    trigger    resistance    ultimately    mouse    acquires    occurs    cancer    questions    knew    homeostasis    progression    procr    poorly    mechanisms    promotion    conditional    events    tumors    phenotype    biology    pi3k    heterogeneity    initiate    responsible    reports    one    hypothesize    panel    patients    therapies    generate    gene    hyperactive    tumor    shown    lineage    stem    tracing    differentiation    model    transformation    explored    mutations    preclinical    proliferation    eventual    chemotherapy    inhibitors    contribution    origin    expression    models    accumulating    oncogenic    ing    combination    biomarkers    tissue    first    genetic    found    event    coding    pinpoint    suggests    portrait    hotspot    clinical    e545k    molecular   

Project "MSCFate" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT BASEL 

Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051
website: www.unibas.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://bentireslab.org/
 Total cost 175˙419 €
 EC max contribution 175˙419 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 175˙419.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

One of the most challenging questions in breast cancer biology is to elucidate the origin of tumor heterogeneity and its contribution to therapy failure. Accumulating evidence suggests that the cell-of-origin, the cell that acquires the first oncogenic event, may define the molecular portrait of the resulting tumor. The fate of mammary Stem Cells (MSC) upon oncogenic perturbation has been poorly explored. Moreover, the Phosphoinositide 3-kinase (PI3K) pathway regulates proliferation/differentiation of MSC and is found hyperactive in breast cancer cells, for example through mutations in PIK3CA, the gene coding for its catalytic subunit. I hypothesize that expression of PIK3CA mutations will perturb mammary tissue homeostasis, initiate mammary cancer and trigger formation of stem-like cancer cells. Using state-of-the-art in situ genetic lineage tracing, I will determine the fate of MSC (identified recently as Procr cells) after conditional expression of PIK3CA hotspot mutations (H1047R, E545K). I will also characterize early molecular events responsible for promotion of transformation (Aim 1). When tumors develop, I will determine tumor phenotype and eventual progression to metastasis (Aim 2). Consequently, this study will generate a new mouse model of breast cancer that will be useful for preclinical studies. A panel of PI3K inhibitors is currently under Clinical investigation and clinical reports have shown that the combination of standard chemotherapy with PI3K inhibitors reduces tumor growth but drug-resistance often occurs. To identify resistance mechanisms to PI3K inhibitors, I will generate in vivo models of drug-resistance (Aim 3). My studies will use both hypothesis driven and unbiased approaches, they should: 1. better elucidate transformation of MSC and the resulting tumor heterogeneity, 2. pinpoint novel targets/biomarkers. Ultimately this knew knowledge should result in better therapies for patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MSCFATE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MSCFATE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

RealFlex (2019)

Real-time simulator-driver design and manufacturing based on flexible systems

Read More  

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More